Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 423

1.

Accuracy and Feasibility of an Android-Based Digital Assessment Tool for Post Stroke Visual Disorders-The StrokeVision App.

Quinn TJ, Livingstone I, Weir A, Shaw R, Breckenridge A, McAlpine C, Tarbert CM.

Front Neurol. 2018 Mar 28;9:146. doi: 10.3389/fneur.2018.00146. eCollection 2018.

2.

Accelerated approval of medicines: fit for purpose?

Breckenridge A, Liberti L.

Nat Rev Drug Discov. 2018 Jan 5. doi: 10.1038/nrd.2017.245. [Epub ahead of print]

PMID:
29302066
3.

Regulatory Consequences of "Brexit" for the Development of Medicinal Products.

Jackson EL, Feldschreiber P, Breckenridge A.

Clin Pharmacol Ther. 2017 Aug;102(2):183-184. doi: 10.1002/cpt.706. Epub 2017 May 27.

PMID:
28555841
4.

FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines.

Liberti L, Bujar M, Breckenridge A, Hoekman J, McAuslane N, Stolk P, Leufkens H.

Front Pharmacol. 2017 Apr 3;8:161. doi: 10.3389/fphar.2017.00161. eCollection 2017.

5.

Factors related to drug approvals: predictors of outcome?

Liberti L, Breckenridge A, Hoekman J, McAuslane N, Stolk P, Leufkens H.

Drug Discov Today. 2017 Jun;22(6):937-946. doi: 10.1016/j.drudis.2017.03.003. Epub 2017 Mar 10. Review.

PMID:
28288783
6.

Poor medication adherence in clinical trials: consequences and solutions.

Breckenridge A, Aronson JK, Blaschke TF, Hartman D, Peck CC, Vrijens B.

Nat Rev Drug Discov. 2017 Mar;16(3):149-150. doi: 10.1038/nrd.2017.1. Epub 2017 Feb 3.

PMID:
28154411
7.

Psilocybin: promising results in double-blind trials require confirmation by real-world evidence.

Breckenridge A, Grobbee DE.

J Psychopharmacol. 2016 Dec;30(12):1218-1219. No abstract available.

PMID:
27909175
8.

Precision medicine and the changing role of regulatory agencies.

Breckenridge A, Eichler HG, Jarow JP.

Nat Rev Drug Discov. 2016 Dec;15(12):805-806. doi: 10.1038/nrd.2016.206. Epub 2016 Oct 14.

PMID:
27739512
9.

Baseline Inflammatory Biomarkers Identify Subgroups of HIV-Infected African Children With Differing Responses to Antiretroviral Therapy.

Prendergast AJ, Szubert AJ, Berejena C, Pimundu G, Pala P, Shonhai A, Musiime V, Bwakura-Dangarembizi M, Poulsom H, Hunter P, Musoke P, Kihembo M, Munderi P, Gibb DM, Spyer M, Walker AS, Klein N; ARROW Trial Team.

J Infect Dis. 2016 Jul 15;214(2):226-36. doi: 10.1093/infdis/jiw148. Epub 2016 May 18.

10.

Prof. John Urquhart.

Breckenridge A, Hughes D.

Br J Clin Pharmacol. 2016 Aug;82(2):573. doi: 10.1111/bcp.12974. Epub 2016 May 2. No abstract available.

11.

Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy.

Crook AM, Turkova A, Musiime V, Bwakura-Dangarembizi M, Bakeera-Kitaka S, Nahirya-Ntege P, Thomason M, Mugyenyi P, Musoke P, Kekitiinwa A, Munderi P, Nathoo K, Prendergast AJ, Walker AS, Gibb DM; ARROW Trial Team.

BMC Med. 2016 Mar 23;14:50. doi: 10.1186/s12916-016-0593-7.

12.

Accelerating access to new medicines: Current status of facilitated regulatory pathways used by emerging regulatory authorities.

Liberti L, Breckenridge A, Hoekman J, Leufkens H, Lumpkin M, McAuslane N, Stolk P, Zhi K, Rägo L.

J Public Health Policy. 2016 Mar 10. doi: 10.1057/jphp.2016.8. [Epub ahead of print]

PMID:
26961261
13.

The Impact of Different CD4 Cell-Count Monitoring and Switching Strategies on Mortality in HIV-Infected African Adults on Antiretroviral Therapy: An Application of Dynamic Marginal Structural Models.

Ford D, Robins JM, Petersen ML, Gibb DM, Gilks CF, Mugyenyi P, Grosskurth H, Hakim J, Katabira E, Babiker AG, Walker AS; DART Trial Team.

Am J Epidemiol. 2015 Oct 1;182(7):633-43. doi: 10.1093/aje/kwv083. Epub 2015 Aug 26.

14.

Single-dose nevirapine exposure does not affect response to antiretroviral therapy in HIV-infected African children aged below 3 years.

Musoke P, Szubert AJ, Musiime V, Nathoo K, Nahirya-Ntege P, Mutasa K, Williams DE, Prendergast AJ, Spyer M, Walker AS, Gibb DM; ARROW Trial Team.

AIDS. 2015 Aug 24;29(13):1623-1632. doi: 10.1097/QAD.0000000000000749.

15.

Observations on Three Endpoint Properties and Their Relationship to Regulatory Outcomes of European Oncology Marketing Applications.

Liberti L, Stolk P, McAuslane JN, Schellens J, Breckenridge AM, Leufkens H.

Oncologist. 2015 Jun;20(6):683-91. doi: 10.1634/theoncologist.2014-0297. Epub 2015 May 6.

16.

After thalidomide - do we have the right balance between public health and intellectual property.

Feldschreiber P, Breckenridge A.

Rev Recent Clin Trials. 2015;10(1):15-8.

PMID:
25925884
17.

Adaptive licensing and facilitated regulatory pathways: A survey of stakeholder perceptions.

Liberti L, Stolk P, McAuslane N, Somauroo A, Breckenridge AM, Leufkens HG.

Clin Pharmacol Ther. 2015 Nov;98(5):477-9. doi: 10.1002/cpt.140. Epub 2015 Jun 30. Review. No abstract available.

PMID:
25877216
18.

Structured observations reveal slow HIV-1 CTL escape.

Roberts HE, Hurst J, Robinson N, Brown H, Flanagan P, Vass L, Fidler S, Weber J, Babiker A, Phillips RE, McLean AR, Frater J; SPARTAC trial investigators.

PLoS Genet. 2015 Feb 2;11(2):e1004914. doi: 10.1371/journal.pgen.1004914. eCollection 2015 Feb.

19.

HIV-1 DNA predicts disease progression and post-treatment virological control.

Williams JP, Hurst J, Stöhr W, Robinson N, Brown H, Fisher M, Kinloch S, Cooper D, Schechter M, Tambussi G, Fidler S, Carrington M, Babiker A, Weber J, Koelsch KK, Kelleher AD, Phillips RE, Frater J; SPARTACTrial Investigators.

Elife. 2014 Sep 12;3:e03821. doi: 10.7554/eLife.03821.

20.

The burden of adverse drug events.

Breckenridge A.

Br J Clin Pharmacol. 2015 Oct;80(4):785-7. doi: 10.1111/bcp.12507. Epub 2015 Jun 1.

Supplemental Content

Loading ...
Support Center